An oral immunotherapy aimed at grass and pollen allergies has a benefit and safety profile that supports its approval, according...
Stallergenes, announced that the FDA has approved Oralair, the first immunotherapy tablet to be available in the U.S. for the...
Stallergenes Greer announced that it has received approval from the FDA for the extension of the indication for Oralair (Sweet...
The Board of Directors of Stallergenes S.A. has reviewed a project submitted by its majority shareholder, Ares Life Sciences, to...